Workflow
Candel Therapeutics(CADL) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Research and Development Expenses: Research and development expenses were 7.0millionforthesecondquarterof2025comparedto7.0 million for the second quarter of 2025 compared to 5.0 million for the second quarter of 2024. The increase was primarily due to an increase in manufacturing costs in support of the Company's CAN- 2409 programs, partially offset by a decrease in employee-related expenses, which was driven primarily from a reduction in stock-based compensation expense. Research and development expenses included a non-cash stock compe ...